SEHK:1093
SEHK:1093Pharmaceuticals

CSPC Pharmaceutical Group (SEHK:1093) valuation after new CEO appointment and SYH2085 influenza trial approval

The latest move at CSPC Pharmaceutical Group (SEHK:1093) blends leadership change with pipeline progress, as the company installs a new CEO and secures trial approval for its SYH2085 influenza candidate. See our latest analysis for CSPC Pharmaceutical Group. The market seems to like this mix of fresh leadership and R&D momentum, with CSPC Pharmaceutical Group's 1 day share price return of 7.64 percent and 7 day share price return of 20.65 percent pushing the stock to HK$8.88. This backs up an...
SEHK:881
SEHK:881Specialty Retail

Zhongsheng Group Holdings (SEHK:881): Assessing Valuation After Audit Committee Leadership Transition

Zhongsheng Group Holdings (SEHK:881) just overhauled a key part of its governance, with long serving audit committee chair Ying Wei stepping down and tax specialist Bai Fengjiu taking over leadership of audit oversight. See our latest analysis for Zhongsheng Group Holdings. The governance refresh comes after a tough stretch, with a 90 day share price return of negative 19.33 percent and a three year total shareholder return of negative 67.17 percent. Investors will be watching to see if...
SEHK:2020
SEHK:2020Luxury

Assessing ANTA Sports Products (SEHK:2020) Valuation After Its Strengthened Sustainability Governance Framework Update

ANTA Sports Products (SEHK:2020) just sharpened its governance playbook by formally revising the mandate of its Sustainability Committee to tighten board oversight of ESG strategy, risk management, and disclosure across the group. See our latest analysis for ANTA Sports Products. That stronger ESG oversight comes as the share price sits at HK$82.25, with an 8.01 percent year to date share price return but a weaker 5 year total shareholder return of negative 24.19 percent. This suggests long...
SEHK:241
SEHK:241Consumer Retailing

How Investors May Respond To Alibaba Health Information Technology (SEHK:241) CEO Shen Difan Also Becoming Chairman

Alibaba Health Information Technology Limited has announced that, effective December 15, 2025, chief executive officer Shen Difan has also been appointed Chairman and head of the Nomination Committee, while former Chairman and non-executive Director Zhu resigned for personal reasons. This move consolidates leadership roles in one individual and formally departs from Hong Kong’s corporate governance code provision that encourages separating the chairman and CEO positions, putting board...
SEHK:9633
SEHK:9633Beverage

Is Nongfu Spring (SEHK:9633) Turning R&D Control Into a Lasting Brand Advantage?

In December 2025, Nongfu SPRING Co., Ltd. announced renewed three-year framework agreements with Yangshengtang Group covering basic R&D, testing services, and purchasing arrangements effective from January 1, 2026 to December 31, 2028. The renewed R&D and test service framework centralizes intellectual property ownership for work products with Nongfu’s group, highlighting how the company is formalizing control over innovation supporting its expanding beverage portfolio. With new R&D...
SEHK:1681
SEHK:1681Pharmaceuticals

3 Asian Stocks Estimated To Be Trading At Discounts Of Up To 37%

Amid recent developments in Asia's financial landscape, including the Bank of Japan raising its benchmark interest rate to a 30-year high and mixed signals from China's economic indicators, investors are keenly observing opportunities for value in the region. In this context, identifying stocks that are trading at a discount can be particularly appealing, as they may offer potential upside when market conditions stabilize or improve.
SEHK:2367
SEHK:2367Personal Products

Giant Biogene Holding (SEHK:2367): Assessing Valuation After Launching a 10% Share Buyback Program

Giant Biogene Holding (SEHK:2367) has kicked off a sizeable share repurchase program, with approval to buy back up to 10% of its share capital. This move puts capital allocation firmly in the spotlight for investors. See our latest analysis for Giant Biogene Holding. The buyback comes after a tough stretch, with a 90 day share price return of negative 41.32 percent, but a recent 4.40 percent 7 day share price return around HK$36.06 hints that sentiment may be stabilising rather than sliding...
SEHK:883
SEHK:883Oil and Gas

CNOOC (SEHK:883): Revisiting Valuation After a Recent Share Price Climb

CNOOC (SEHK:883) has quietly outperformed this year, and that kind of steady move often slips under the radar. With the share price still below many valuation estimates, investors are revisiting the long term case. See our latest analysis for CNOOC. The recent climb to around HK$20.8 follows a solid 90 day share price return near 10 percent. At the same time, a far stronger multiyear total shareholder return suggests momentum is still broadly constructive rather than exhausted. If CNOOC has...